Deals review
- Deals review
- Deal details
PARALLELE BIOSCIENCE AND MERCK COLLABORATE TO DISCOVER GENETIC VARIATIONS IN DRUG TARGETS
In order to access this content you must be logged in and have a subscription to Pharmalicensing Intelligence.
Pharmalicensing Intelligence is a one-stop environment for time-conscious executives. Keeping you abreast of the latest developments in the life sciences industry, saving you time and money when you need it most.
Related deals
Parallele Bioscience and Merck collaborate to discover genetic variations in cancer
Roche and ParAllele BioScience collaborate to study diabetes genetics
Affymetrix, ParAllele and Cambridge University Collaborate For Large-Scale Genetic Study of Diabetes
Affymetrix completes acquisition of ParAllele BioScience
Genaissance and ParAllele BioScience Sign License and Co-Marketing Agreement
Affymetrix signs agreement to acquire ParAllele BioScience
Related categories
- Therapeutic target
- Oncology
- Industry sector
- Drug discovery
- Genomics
More deals
Latest deals
- Biovator and BASF sign technology development agreement
- Agfa HealthCare signs four-year agreement with Chinese partners for distribution of radiography solutions, potentially worth 500 million US dollar
- Omnicare Announces Acquisition of Continuing Care Rx
- Nabi Biopharmaceuticals Announces Long-Term Manufacturing Agreement With Diosynth RTP
- GreenVax Selects Xcellerex XDR Single-Use Bioreactors for New Vaccine and Biotherapeutics Program
Most viewed deals
- Recommended acquisition of Acambis plc ("Acambis") by Sanofi Pasteur Holding ("Sanofi Pasteur") by way of scheme of arrangement Posting of Scheme Document
- Omnicare Announces Acquisition of Continuing Care Rx
- Bayer CropScience and Janssen PMP conclude research agreement:
- Nabi Biopharmaceuticals Announces Long-Term Manufacturing Agreement With Diosynth RTP
- Biovator and BASF sign technology development agreement
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us